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Abstract
Background: This study aimed to compare the adverse clinical outcomes associated with a short and a prolonged
duration of Dual Anti-Platelet Therapy (DAPT) in patients with Diabetes Mellitus (DM) after undergoing Percutaneous
Coronary Intervention (PCI).
Methods: Medline/PubMed, EMBASE and the Cochrane library were searched for studies comparing the short and
prolonged DAPT use in patients with DM. Adverse outcomes were considered as the clinical endpoints in this analysis.
Odds Ratios (OR) with 95 % Confidence Intervals (CI) were used to express the pooled effect on discontinuous variables
and the pooled analyses were performed with RevMan 5.3.
Results: Fifteen studies with a total number of 25,742 patients with DM were included in this current analysis which
showed no significant differences in primary endpoints, net clinical outcomes, myocardial infarction and stroke with
OR: 1.03, 95 % CI: 0.65–1.64; P = 0.90, OR: 0.96, 95 % CI: 0.69–1.34; P = 0.81, OR: 0.85, 95 % CI: 0.70–1.04; P = 0.12 and OR:
0.94, 95 % CI: 0.65–1.36; P = 0.75 respectively. Revascularization was also similar between these 2 groups of patients
with DM. However, even if mortality favored prolonged DAPT use, with OR: 0.87, 95 % CI: 0.76–1.00; P = 0.05, the result
only approached significance. Also, stent thrombosis insignificantly favored a prolonged DAPT duration with OR: 0.56,
95 % CI: 0.27–1.17; P = 0.12. Thrombolysis In Myocardial Infarction (TIMI) defined major and minor bleeding
were not significantly different in these diabetic patients with OR: 0.91, 95 % CI: 0.60–1.37; P = 0.65 and OR: 1.
08, 95 % CI: 0.62–1.91; P = 0.78 respectively. However, bleeding defined by the Bleeding Academic Research
Consortium (BARC) classification was significantly higher with a prolonged DAPT use in these diabetic patients
with OR: 1.92, 95 % CI: 1.58–2.34; P < 0.00001.
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Conclusion: Following PCI, a prolonged DAPT use was associated with similar adverse clinical outcomes but with a
significantly increased BARC defined bleeding compared to a short term DAPT use in these patients with DM.
However, even if mortality and stent thrombosis favored a prolonged DAPT use, these outcomes only either
reached statistical significance or were insignificant respectively, showing that a clear decision about recommending a
prolonged duration of DAPT to patients with DM might not be possible at this moment, warranting further research in
this particular subgroup.
Keywords: Dual antiplatelet therapy, Percutaneous coronary intervention, Diabetes mellitus, Drug eluting stents,
Clopidogrel, Stent thrombosis, Bleeding events
Abbreviations: ACS, Acute coronary syndrome; BARC, Bleeding academic research consortium; DAPT, Dual antiplatelet
therapy; DES, Drug eluting stents; DM, Diabetes mellitus; PCI, Percutaneous coronary intervention; TIMI, Thrombolysis in
myocardial infarction
Background
According to guidelines, Dual Anti-Platelet Therapy
(DAPT) with aspirin and P2Y12 inhibitors, mainly clopi-
dogrel, is recommended for at least one year following
Percutaneous Coronary Intervention (PCI) with Drug
Eluting Stents (DES) [1]. However, even in this new era,
several Randomized Controlled Trials (RCTs) still could
not predict the exact duration of DAPT use and sug-
gested that this issue might possibly be solved only using
a larger number of randomized patients following PCI
with DES [2]. To be more clear, in a previously pub-
lished study comparing 6 months with 12 months DAPT
use, the authors stated that larger trials would be able to
completely solve this issue [3]. Even if several meta-
analyses comparing the short and prolonged DAPT use
in the general population following PCI showed a longer
duration of DAPT to be associated with favorable clin-
ical outcomes [4], other meta-analyses showed no bene-
fits of a prolonged DAPT duration [5] giving rise to
controversies. However, whether these results also apply
to the subgroup of patients with Diabetes Mellitus (DM)
have seldom been studied. Therefore, this study aimed
to compare the adverse clinical outcomes associated
with a short and prolonged duration of DAPT use in
patients with DM following PCI.
Methods
Data sources and search strategy
Medline/PubMed, EMBASE and the Cochrane library
were searched for studies comparing the short and pro-
longed use of DAPT in patients with Acute Coronary
Syndrome (ACS) following PCI by typing the words
‘dual anti-platelet therapy, diabetes mellitus and percu-
taneous coronary intervention’. Another search was
performed using the phrase ‘prolonged clopidogrel use,
diabetes mellitus and percutaneous coronary interven-
tion’. To widen this search, the abbreviations ‘DAPT,
DM, and PCI’ as well as the term ‘coronary angioplasty’
were also used. In addition, reference lists of suitable
studies were also reviewed for relevant articles. Only
articles published in English were considered in this
search process.
Inclusion and exclusion criteria
Studies were included if:
(a)They were randomized trials or observational studies.
(b)They compared short and prolonged DAPT use and
included patients with DM.
(c)They reported adverse outcomes as their clinical
endpoints.
(d)They were published in English.
Studies were excluded if:
(a)They were meta-analyses, case studies or editorials.
(b)They did not involve patients with DM.
(c)They did not report adverse outcomes as their
clinical endpoints.
(d)They did not compare short with prolonged DAPT
use, but instead, compared aspirin monotherapy
with DAPT following PCI.
(e)They were duplicates or involved the same trial.
Definitions, outcomes and follow up
DM was defined as a state of high blood sugar levels ob-
served at least on two separate occasions, with a fasting
blood glucose test or an oral glucose tolerance test, with or
without symptoms (asymptomatic) such as polydipsia (fre-
quent thirst), polyuria (frequent urination) and weight loss.
Adverse clinical outcomes which were analyzed in this
study included:
(a)Primary endpoint which was a composite endpoint
of all-cause death, Myocardial Infarction (MI),
stroke, revascularization and stent thrombosis.
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(b)MI (any type or any classification of MI) was
relevant including the universal definition [6].
(c)Target Lesion Revascularization (TLR).
(d)Target Vessel Revascularization (TVR).
(e)All-cause death (cardiac and non-cardiac).
(f ) Stroke.
(g)Net Adverse Clinical and Cerebral Events (NACCE)
were defined as a composite of all-cause death, all
MI, stroke or major bleeding.
(h)Stent thrombosis which was defined by the
Academic Research Consortium (ARC) [7].
(i) Bleeding:
(1)All/Any bleeding.
(2)Major and Minor bleeding defined by Thrombolysis
in Myocardial Infarction (TIMI) [8].
(3)Bleeding defined according to the Bleeding
Academic Research Consortium (BARC) [9] which
was further divided into BARC type 2, BARC type 3
and BARC type 5.
The adverse clinical outcomes reported have been
listed in Table 1.
Short and prolonged duration of DAPT
Short and prolonged duration of DAPT use were based
on the following criteria:
If the short term DAPT duration period was 3 months,
its corresponding prolonged duration period should be
more than 3 months (6, 12, 24, or more).
If the short term duration of DAPT was 6 months, its
corresponding prolonged duration period should be
more than 6 months (12, 18, 24, or more).
If the short term duration of DAPT use was 12 months,
its corresponding prolonged duration period should be
more than 12 months.
Therefore, a prolonged duration of DAPT was defined
as the use of DAPT during a period of time longer
than the actual short term duration corresponding to
that particular trial. Different trials had different short
and prolonged duration of DAPT use. Table 2 further
illustrated the short and prolonged duration periods
of DAPT use in each of the studies included in this
meta-analysis.
Data extraction and review
Two authors (PKB and CMY) independently assessed
the studies involved and reviewed the methodological
quality of each eligible trial. Information regarding the
study/trial names, time period of patients’ enrollment,
adverse clinical outcomes reported, the follow up pe-
riods, data concerning the total number of patients with
DM classified into the short and prolonged DAPT
groups respectively, the total number of clinical events
reported in each subgroup, as well as information con-
cerning the baseline features of the patients were carefully
extracted and cross checked. During the data extraction
process, any disagreement which occurred between these
two authors was carefully discussed, and if they could not
reach a consensus, the disagreement was solved and a
final decision was made by the third author (FH). The bias
risk among the trials (low risk, moderate risk and high
risk) was assessed with the components recommended by
the Cochrane Collaboration [10]. The six components of
the bias risk were as follow:
Table 1 Reported outcomes
Studies Reported outcomes Follow up period Bias grade
Brar2008 Death, MI 9.7 months -
I-LOVE IT 2 NACCE, death, MI, stroke, TVR, TLR, ST, all bleeding, major bleeding 12 and 18 months B
ISAR-SAFE Primary endpoints, death, MI, ST, stroke, TIMI major and minor bleeding, BARC bleeding 9 months B
Tarantini2016 Death, MI, composite endpoints, stent thrombosis, BARC type 3 or 5 bleeding, stroke, revascularization 1 year -
ARCTIC Primary endpoints, Death, MI, ST, stroke, revascularization 17 months B
OPTIMIZE NACCE, death, MI, stroke, ST, major bleeding, TLR, TVR, any bleeding 1 year B
RESET Primary endpoints, death, MI, TVR, ST, major and minor bleeding, stroke 1 year B
EXCELLENT Death, MI, stroke, TVR, TLR, ST, any bleeding, TIMI major bleeding 1 year B
PEGASUS Death, MI, stroke, TIMI major and minor bleeding 3 years B
DAPT ST, MACCEs, death, stroke, MI, BARC type 2,3 or 5 12 to 30 months B
Sardella2011 Death, MI, stroke, TIMI minor bleeding, revascularization 2 years -
PRODIGY Death, MI, stroke, ST, TLR, TVR, TIMI major and minor bleeding, BARC bleeding 2 years B
Thukkani2015 Death, MI, Stroke 4 years -
ENDEAVOR Death, MI, ST (definite and probable), stroke, major bleeding 2 years B
ITALIC Primary endpoints, minor bleeding, minimal bleeding, death, MI, stroke, TVR, ST, major bleeding 1 year B
Abbreviations: MI myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, TLR target lesion revascularization, NACCE net adverse clinical and
cerebral events, BARC bleeding academic research consortium, TIMI thrombolysis in myocardial infarction
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A. Sequence generation
B. Allocation sequence concealment
C. Blinding of participants and personnel
D. Blinding of outcome assessment
E. Incomplete outcome data
F. Selective outcome reporting and other potential bias
The trials included in this study were analyzed accord-
ing to these six components and a bias grade was given
accordingly after a careful assessment. A grade ranging
from A to E was considered whereby grade A was allo-
cated if an extremely low risk of bias was reported, while
a grade E was allocated if a very high risk of bias was
observed. Note that these bias grades were just an ap-
proximation according to what the authors were able to
assess. The bias risk grades allocated to each trial were
provided in Table 1. Note that observational studies
were ignored during this assessment.
Methodological and statistical analysis
Recommendations of the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) state-
ment were followed in this study [11]. Heterogeneity
among the subgroups was assessed using the Cochrane
Q-statistic test whereby a P value less than 0 · 05 was
considered statistically significant whereas P value ≥ 0.05
was considered statistically insignificant. I2-statistic test
which also assessed heterogeneity, whereby an I2 with a
low percentage (<25 %) represented a low heterogeneity,
an I2 with a percentage between 25 and 50 %
represented a moderate heterogeneity and an I2 with a
high percentage above 50 % denoted an increasing het-
erogeneity. If I2 was less than 50 %, a fixed effect model
was used during this subgroup analysis. However, if I2
was more than 50 %, a random effect model was used.
Publication bias was visually estimated by assessing fun-
nel plots. Odds Ratios (OR) with 95 % Confidence Inter-
vals (CIs) were calculated for categorical variables and
the pooled analyses were performed with RevMan 5.3
software. Ethical committee or medical institutional
board approval was not required since this is a system-
atic review and meta-analysis of several studies.
Results
Search result
Two thousand two hundred seventy four articles were
obtained from PubMed/Medline, EMBASE, the Cochrane
Library and from suitable reference lists. After a careful
selection and assessment of titles and abstracts, 2168
articles were eliminated since they were not related to
the topic of this research. Among the 106 remaining ar-
ticles, 52 articles were further eliminated since they
were duplicates. Fifty-four full-text articles were assessed
for eligibility. Ten studies were further eliminated since
they were meta-analyses, 11 studies were case studies, 2
studies were protocol of future ongoing trials, 6 articles
were letter to editors, and 10 articles were associated with
the same trial. Finally, 15 studies (Brar2008 [12], I-LOVE
IT 2 [13], ISAR-SAFE [14], Tarantini2016 [15], ARCTIC
[16], OPTIMIZE [17], RESET [18], EXCELLENT [3],
Table 2 General features of the studies included
Features No of DM patients in
the short term group (n)
No of DM patients in the
long term group (n)
Type of study Enrollment period Duration of DAPT
use (months)
Brar2008 378 371 OB 2002–2004 <9 vs > 9
I-LOVE IT 2 211 203 RCT 2012–2015 6 vs 12
ISAR-SAFE 495 484 RCT 2008–2014 6 vs 12
Tarantini2016 206 223 RCT 2009–2014 6 vs > 12
ARCTIC 222 198 RCT 2009–2011 <12 vs >12
OPTIMIZE 554 549 RCT 2010–2015 3 vs 12
RESET 316 305 RCT 2009–2010 3 vs 12
EXCELLENT 272 278 RCT 2008–2009 6 vs 12
PEGASUS 1950 1574 RCT 2010–2013 <12 vs > 12
DAPT 1481 1556 RCT 2009–2011 12 vs 30
Sardella2011 133 139 OB 2005–2006 12 vs > 12
PRODIGY 35 36 RCT 2006–2012 6 vs 24
Thukkani2015 6568 5949 OB 2002–2006 12 vs > 12
ENDEAVOR 198 183 RCT 2005–2011 12 vs > 24
ITALIC 331 344 RCT 2011–2015 6 vs 24
Total no of patients (n) 13,350 12,392
Abbreviations: DM diabetes mellitus, DAPT dual antiplatelet therapy, RCT randomized controlled trials, OS observational studies
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PEGASUS [19], DAPT [20], Sardella2011 [21], PRODIGY
[22], Thukkani2015 [23], ENDEAVOR [24], ITALIC [25])
that satisfied all the inclusion and exclusion criteria of this
current analysis, were included. The flow diagram repre-
senting the study selection has been illustrated in Fig. 1.
Study Tarantini2016 [15] was a sub-study of the SE-
CURITY trial [26] including patients only with DM and
trials DES LATE [27] and REAL-LATE ZEST-LATE [28]
were excluded because they compared aspirin monother-
apy versus DAPT, instead of prolonged DAPT use versus
short term DAPT use.
General features of the studies included
A total number of 25,742 patients with DM (13,350 pa-
tients assigned to short term DAPT group whereas
12,392 patients assigned to prolonged DAPT group)
were included. Patients were enrolled from the year
2002 to the year 2015. The general features of the stud-
ies included have been listed in Table 2.
Baseline features of the studies included
Table 3 summarized the baseline characteristics of the
patients included in this meta-analysis.
Mean age was reported in years. Patients who were en-
rolled in this study had a mean age ranging from 60.0 to
70.0 years. Trials ITALIC [25], ISAR-SAFE [14] and
ARCTIC [16] had a majority of males patients. Trial
ISAR-SAFE [14] and study Thukkani2015 [23] involved
a high number of patients with hypertension. According
to the baseline features reported, no significant differ-
ence was observed among patients assigned to either a
short or prolonged duration of DAPT use.
Main analysis
Results of this analysis have been summarized in
Table 4.
Fig. 1 Flow diagram representing the study selection
Table 3 Baseline features of the studies included
Studies Mean age Males (%) HT (%) Ds (%) Cs (%)
S/L S/L S/L S/L S/L
Brar2008 62.9/62.9 70.0/70.0 - - -
I-LOVE IT 2 60.4/60.0 67.2/68.7 61.0/64.8 25.3/23.4 24.2/24.9
ISAR-SAFE 67.2/67.2 80.7/80.5 90.1/91.5 87.5/87.4 24.9/25.7
Tarantini2016 65.5/66.7 71.8/74.0 82.5/80.3 69.4/70.9 18.9/20.2
ARCTIC 64.0/64.0 81.0/80.0 62.0/59.0 68.0/67.0 24.0/23.0
OPTIMIZE 61.3/61.9 63.5/63.1 86.4/88.2 63.2/63.7 18.6/17.3
RESET 62.4/62.4 64.4/62.9 62.3/61.4 57.7/59.9 25.2/22.8
EXCELLENT 63.0/62.4 65.1/63.9 72.7/73.8 75.2/76.3 27.4/25.8
PEGASUS 65.0/66.0 77.0/77.0 76.0/76.0 76.0/77.0 16.0/17.0
DAPT 61.6/61.8 74.0/75.3 74.0/75.8 - 24.7/24.6
Sardella2011 61.9/61.2 78.2/81.3 76.7/74.8 57.1/64.0 48.1/62.6
PRODIGY 70.0/68.0 75.0/78.0 71.0/72.0 62.0/66.0 12.0/15.0
Thukkani2015 64.3/64.3 98.5/98.5 97.1/97.8 - 34.8/33.3
ENDEAVOR 62.4/63.6 69.6/69.4 73.6/79.5 80.5/81.4 52.3/56.2
ITALIC 61.7/61.5 80.8/79.2 65.2/64.7 67.1/67.1 50.9/52.7
Abbreviations: S short term DAPT use, L prolonged DAPT use, HT hypertension,
Ds dyslipidemia, Cs current smoking
Table 4 Results of this analysis
Outcomes analyzed OR with 95 % CI P value I2 (%)
Primary endpoints 1.03 [0.65–1.64] 0.90 0
Net clinical outcomes 0.96 [0.69–1.34] 0.81 0
Mortality 0.87 [0.76–1.00] 0.05 0
MI 0.85 [0.70–1.04] 0.12 0
TVR 0.85 [0.58–1.24] 0.39 0
TLR 0.90 [0.57–1.41] 0.63 0
Stroke 0.94 [0.65–1.36] 0.75 0
ST (definite or probable) 0.56 [0.27–1.17] 0.12 0
Definite ST 0.63 [0.08–4.79] 0.65 0
TIMI major bleeding 0.91 [0.60–1.37] 0.65 0
TIMI minor bleeding 1.08 [0.62–1.91] 0.78 0
BARC defined bleeding 1.92 [1.58–2.34] 0.00001 0
BARC type 2 1.98 [1.50–2.61] 0.00001 0
BARC type 3 1.78 [1.34–2.37] 0.0001 0
BARC type 5 1.40 [0.59–3.30] 0.44 0
Abbreviations: OR odds ratios, CI confidence intervals, MI myocardial infarction,
TVR target vessel revascularization, TLR target lesion revascularization, ST stent
thrombosis, TIMI thrombolysis in myocardial infarction, BARC bleeding
academic research consortium
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This current analysis showed no significant differences
in primary endpoints and net clinical outcomes in
patients with DM whether with a short or prolonged
treatment period with DAPT with OR: 1.03, 95 % CI:
0.65–1.64; P = 0.90 and OR: 0.96, 95 % CI: 0.69–1.34; P
= 0.81 respectively. MI was also not significantly differ-
ent with OR: 0.85, 95 % CI: 0.70–1.04; P = 0.12. How-
ever, even if mortality favored prolonged DAPT use,
with OR: 0.87, 95 % CI: 0.76–1.00; P = 0.05, the result
only approached statistical significance. These results
have been illustrated in Fig. 2.
TVR and TLR were also similarly manifested between
these 2 groups with OR: 0.85, 95 % CI: 0.58–1.24; P =
0.39 and OR: 0.90, 95 % CI: 0.57–1.41; P = 0.63 respect-
ively. Stroke was also not significantly different with a
short term or prolonged DAPT use with these patients
with DM, with OR: 0.94, 95 % CI: 0.65–1.36; P = 0.75.
However, even if stent thrombosis favored a prolonged
DAPT use with OR: 0.56, 95 % CI: 0.27–1.17; P = 0.12,
this result was not statistically significant. These results
have been illustrated in Fig. 3.
Bleeding events were also analyzed in these patients
with DM. Any bleeding was not significantly different
between a short and a prolonged DAPT use with OR:
1.22, 95 % CI: 0.72–2.08; P = 0.46. TIMI defined major
and minor bleeding were also not significantly different
in these diabetic patients with OR: 0.91, 95 % CI: 0.60–
1.37; P = 0.65 and OR: 1.08, 95 % CI: 0.62–1.91; P = 0.78
respectively. However, bleeding defined by the BARC
classification was significantly higher with a prolonged
Fig. 2 Adverse clinical outcomes associated with a short versus prolonged DAPT use in patients with DM (part 1)
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Fig. 3 Adverse clinical outcomes associated with a short versus prolonged DAPT use in patients with DM (part 2)
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DAPT use in these diabetic patients with OR: 1.92, 95 %
CI: 1.58–2.34; P < 0.00001. When bleeding defined by
BARC classification was further subdivided, a signifi-
cantly higher BARC bleeding types 2 and 3 were ob-
served with a prolonged DAPT use with OR: 1.98, 95 %
CI: 1.50–2.61; P < 0.00001 and OR: 1.78, 95 % CI: 1.34–
2.37; P < 0.0001 respectively. But even if BARC type 5
also favored a short term DAPT use, with OR: 1.40,
95 % CI: 0.59–3.30; P = 0.44, the result was not statisti-
cally significant. Results analyzing bleeding events have
been illustrated in Fig. 4.
Because the duration period of DAPT was not similar
in all the studies included, that is, a few studies had a
short term DAPT duration period of 3 months, 6 months
and 12 months respectively, and a long term DAPT
duration period of 12 months, 18 months or 24 months
respectively, which might have influenced the results of
this analysis, another subgroup analysis was conducted
only with a short term DAPT duration of 6 months
versus a long term duration of 12 months. However, this
analysis also showed no significant difference in net
clinical outcomes, mortality, MI, TVR, TLR, stent
thrombosis and stroke with OR: 0.95, 95 % CI: 0.56–
1.60; P = 0.84, OR: 1.14, 95 % CI: 0.44–2.97; P = 0.79,
OR: 0.79, 95 % CI: 0.39–1.60; P = 0.51, OR: 0.94, 95 %
CI: 0.45–1.96; P = 0.86, OR: 1.01, 95 % CI: 0.45–2.26; P
= 0.99, OR: 0.55, 95 % CI: 0.15–2.01; P = 0.36 and OR:
1.02, 95 % CI: 0.33–3.18; P = 0.97 respectively. These
results comparing 6 months versus 12 months DAPT
use have been illustrated in Fig. 5.
Sensitivity analysis
For all of the above analyses, sensitivity analyses yielded
consistent results. Based on a visual inspection of the
funnel plots obtained, there has been very low evidence
of publication bias for the included studies that assessed
all clinical endpoints reported (including the adverse
clinical outcomes and the bleeding events analyzed) in
these patients with DM. The funnel plots have been
illustrated in Figs. 6 and 7.
Discussion
This study aimed to compare the adverse clinical out-
comes associated with a short and prolonged DAPT use
in patients with DM following PCI. Results of this study
showed that a prolonged duration of DAPT use was not
associated with any significant difference in adverse clin-
ical outcomes when compared to a short term duration
of DAPT use in these patients with DM. The result for
mortality which favored a prolonged DAPT use reached
near significance but was not statistically significant in
this analysis whereas even if stent thrombosis favored a
prolonged DAPT use, the result was also not statistically
significant. In addition, TIMI defined major and minor
bleeding were also not significantly different. However,
bleeding defined according to BARC classification was
significantly higher with the prolonged DAPT use.
In part similar to the results of this current analysis,
the systematic review and meta-analysis comparing the
duration of DAPT following DES implantation showed
short term DAPT use to be associated with a signifi-
cantly lower rate of bleeding, and higher rates of stent
thrombosis [29]. Note that their study involved more
than 30 % of patients with DM. However, their meta-
analysis showed all-cause mortality to be insignificantly
higher in the long term duration group, which was not
the case in our study. In addition, this current study only
showed a significantly increased bleeding rate according
to the BARC classification, without any significant differ-
ence for stent thrombosis. Another meta-analysis pub-
lished by Navarese et al. showed that compared to a
DAPT duration period of 12 months, a short term
DAPT use was associated with a significantly lower rate
of bleeding events, without any apparent increase in
ischemic complications and therefore the authors con-
cluded that a short term DAPT could be considered in
most patients following PCI [5].
Furthermore, the meta-analysis published by Yang et
al. showed no difference in efficacy outcomes associated
with a short or prolonged duration of DAPT use after
intracoronary DES implantation [30]. However, a longer
duration of DAPT (≥12 months) was associated with in-
creased risk of bleeding complications. The study by
Udell et al. also concluded that DAPT use beyond one
year was associated with increased bleeding events, with-
out any increase in cardiovascular mortality [4]. In
addition, the PRODIGY trial which involved more than
20 % of patients with DM, showed a 24 months of clopi-
dogrel use not to be associated with any increase in ad-
verse clinical outcomes compared to the use of
clopidogrel during a short term period of 6 months [31].
This trial compared device specific outcomes relative to
different duration of DAPT in 3 different types of DES
(everolimus eluting stents, paclitaxel eluting stents,
zotarolimus eluting stents) and bare metal stents, sug-
gesting that the optimal duration of DAPT could also
possibly be stent specific.
Moreover, patients with DM showed comparable ad-
verse clinical outcomes to that of patients without DM
whether during a 6-months treatment with DAPT or a
prolonged duration of DAPT following PCI with im-
planted second generation DES [15].
Nevertheless, the study by Valgimigli et al. showed that
along with an increased risk of bleeding associated with
a prolonged duration of DAPT use, an increased risk of
stroke was also observed [32]. However, our results
which involved patients with DM, did not show any sig-
nificant difference in stroke rate between these two
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Fig. 4 Bleeding events associated with a short versus prolonged DAPT use in patients with DM
Bundhun et al. BMC Cardiovascular Disorders  (2016) 16:161 Page 9 of 14
groups. The ITALIC trial also showed no significantly
different bleeding or thrombotic events when 6 months
DAPT use was compared to 24 months DAPT use after
PCI [25]. However, the ITALIC trial involved patients
implanted with newer generation DES and also involved
patients with good response to aspirin.
The study by Siddiqqi et al. which consisted of more
than 50 % of patients with DM, showed a prolonged
Fig. 5 Adverse clinical outcomes associated specifically with 6 versus 12 months DAPT use in patients with DM
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Fig. 6 Funnel plots representing sensitivity analyses
Fig. 7 Funnel plots representing sensitivity analyses
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duration of DAPT not to be associated with any in-
creased risk of bleeding. However, their study involved
patients with chronic kidney disease and the exact type
of bleeding assessed was not specified [33]. The study by
Thukkani et al. also showed results that favored the pro-
longed use of clopidogrel to be associated with a lower
risk of death and MI only in patients with DM implanted
with DES [23]. However, that study did not show any
benefit of prolonged clopidogrel use in patients without
DM or in patients implanted with bare metal stents.
Moreover, the DAPT trial also showed a lower rate of
mortality to be associated with a prolonged use of clopido-
grel after PCI [20]. However, result of this analysis which
involved only patients with DM, did not reach statistical
significance in the subgroup analyzing mortality.
Even if the subgroup analysis of the OPTIMIZE trial
that assessed how short-term DAPT did not show any
significantly increase risk for clinical events at 1 year in
patients with DM undergoing PCI with a specific 2nd
generation DES [34], other studies have shown second
generation DES to be associated with higher adverse
outcomes in patients with DM compared to the general
population [35]. In addition, studies showed increasing
adverse clinical outcomes to be associated with insulin-
treated DM compared to non-insulin treated DM irre-
spective of the duration of DAPT [36, 37].
Furthermore, the observational study conducted by
Eisenstein et al. examining consecutive patients receiving
DES at Duke Heart Center between the year 2000 and
2005, concluded that the extended use of clopidogrel in
patients implanted with DES might be associated with a
lower risk of death and MI [2]. However, the authors
concluded that only larger trials will be able to confirm
their results, but unfortunately, even if this current ana-
lysis involved a pooling of data from several randomized
trials (but only including patients with DM), the result
analyzing mortality only nearly reached statistical signifi-
cance, but was not statistically significant.
Even if the result for stent thrombosis was not signifi-
cant in patients with DM, other studies have shown a
prolonged use of DAPT to be associated with a lower
risk of stent thrombosis compared to a shorter duration
of DAPT use after PCI. To prove this point, the TY-
COON registry showed an extended use of DAPT
(2 years) to be associated with a lower rate of stent
thrombosis following PCI with DES [38]. However, in
contrast, other studies showed clopidogrel use beyond
one year not to reduce the risk of stent thrombosis or
other adverse clinical outcomes after PCI [39].
Previous studies have already compared the clinical
outcomes associated with duration of DAPT in the sub-
set of patients treated for in-stent restenosis [23]. This
current analysis showed compared the adverse clinical
outcomes between a short and prolonged DAPT use in
patients with DM. To be noted, the duration of DAPT
use might vary in other subgroups of patients. As it is
said, one size shoe approach for DAPT duration is
unlikely to fit all the patients, further investigations
including other subgroups of patients such as patients
with chronic obstructive pulmonary disease who under-
went PCI [40, 41], should be conducted.
Novelty
This study is new in several ways. Even if many studies
have compared the short and prolonged use of DAPT
following PCI, this is among the first meta-analyses
comparing the adverse clinical outcomes associated with
the short and prolonged use of DAPT in patients with
DM. Moreover, this analysis involved several newly pub-
lished articles which were not included in other recently
published meta-analyses representing another novelty.
Limitations
Similar to other studies, this study also has limitations.
First of all, due to the small population of patients with
DM, this study might not provide robust results. Sec-
ondly, different studies reported different duration of
DAPT use, as well as different follow up periods. Even
if we have tried to compare only 6 months versus
12 months DAPT use in these patients with DM in
order to solve this particular issue, we might have only
partly succeeded showing that this point should still be
considered as a limitation in this study. Moreover, data
analyzing several bleeding subgroups were limited,
which might have influenced the results.
Conclusion
Following PCI, a prolonged DAPT use was associated
with similar adverse clinical outcomes but with a signifi-
cantly increased BARC defined bleeding compared to a
short term DAPT use in these patients with DM. How-
ever, even if mortality and stent thrombosis favored a pro-
longed DAPT use, these outcomes only either reached
statistical significance or were insignificant respectively,
showing that a clear decision about recommending a pro-
longed duration of DAPT to patients with DM might not
be possible at this moment, warranting further research in
this particular subgroup.
Acknowledgement
This research was supported by Youth Science Foundation of Guangxi Medical
University (No. GXMUYSF201308), Scientific Project of Guangxi Higher Education
(No. KY2015ZD028) and National Natural Science Foundation of China
(No. 81560046).
Funding
There was no external source of funding for this research.
Availability of data and materials
All data and materials used in this research are freely available. References
have been provided.
Bundhun et al. BMC Cardiovascular Disorders  (2016) 16:161 Page 12 of 14
Authors’ contributions
PKB, CMY and FH were responsible for the conception and design, acquisition
of data, analysis and interpretation of data, drafting the initial manuscript and
revising it critically for important intellectual content. PKB wrote this manuscript.
All authors read and approved the final manuscript.
Authors’ information
Dr Pravesh Kumar Bundhun (M.D) is the first author. From the Department
of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical
University, Nanning, Guangxi, China.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval was not applicable for this systematic review and meta-analysis.
Author details
1Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi
Medical University, Nanning, Guangxi 530021, People’s Republic of China.
2Department of Internal Medicine, EALING Hospital, University of
Buckingham, Uxbridge road, Southall, UB1 3HW London, UK.
Received: 30 June 2016 Accepted: 30 July 2016
References
1. Task Force members, Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS
guidelines on myocardial revascularization: the Task Force on Myocardial
Revascularization of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS) developed with
the special contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.
2. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical
outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159–68.
3. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet
therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus
Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized,
multicenter study. Circulation. 2012;125(3):505–13.
4. Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for
secondary prevention of cardiovascular events in the subgroup ofpatients
with previous myocardial infarction: a collaborative meta-analysis of
randomized trials. Eur Heart J. 2016;37(4):390–9.
5. Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet
therapy after percutaneous coronary intervention with drug eluting stents:
meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.
6. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial
infarction. Circulation. 2007;116(22):2634–53.
7. Cutlip DE, Windecker S, Mehran R, Academic Research Consortium, et al.
Clinical end points in coronary stent trials: a case for standardized definitions.
Circulation. 2007;115(17):2344–51.
8. No authors. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I
findings. TIMI Study Group. N Engl J Med. 1985;312(14):932–6.
9. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for
cardiovascular clinical trials: a consensus report from the Bleeding Academic
Research Consortium. Circulation. 2011;123(23):2736–47.
10. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-
analyses. BMJ. 2003;327:557–60.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.
12. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration
and stent type in a diabetic population with de novo coronary artery lesions.
J Am Coll Cardiol. 2008;51(23):2220–7.
13. Han Y, Xu B, Xu K, et al. Six versus 12 months of dual antiplatelet therapy
after implantation of biodegradable polymer sirolimus-ElutingStent:
randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv. 2016;
9(2):e003145.
14. Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. Intracoronary Stenting and
Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet
Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE:
a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of
clopidogrel therapy afterdrug-eluting stenting. Eur Heart J. 2015;36(20):1252–63.
15. Tarantini G, Nai Fovino L, Tellaroli P, et al. Optimal duration of dual antiplatelet
therapy after second-generation drug-eluting stent implantation in patientswith
diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation
Followed By Six- VersusTwelve-Month Dual Antiplatelet Therapy)-diabetes
substudy. Int J Cardiol. 2016;207:168–76.
16. Collet JP, Silvain J, Barthélémy O, ARCTIC investigators, et al. Dual-antiplatelet
treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-
Interruption): a randomised trial. Lancet. 2014;384(9954):1577–85.
17. Feres F, Costa RA, Abizaid A, OPTIMIZE TrialInvestigators, et al. Three vs
twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:
the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510–22.
18. Kim BK, Hong MK, Shin DH, RESET Investigators, et al. A new strategy for
discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and
Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-
eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–8.
19. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T,
Budaj A, Goto S, López-Sendón J, Diaz R, Dalby A, Van de Werf F, Ardissino
D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E,
Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time
from P2Y12 inhibitor withdrawal in patients withprior myocardial infarction:
insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37(14):1133–42.
20. Mauri L, Kereiakes DJ, Yeh RW, DAPT Study Investigators, et al. Twelve or
30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J
Med. 2014;371(23):2155–66.
21. Sardella G, Mancone M, Biondi-Zoccai G, et al. Beneficial impact of prolonged
dual antiplatelet therapy after drug-eluting stent implantation. J Interv Cardiol.
2012;25(6):596–603.
22. Campo G, Tebaldi M, et al. Short- versus long-term duration of dual antiplatelet
therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy
(Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia). J Am Coll Cardiol. 2014;63(6):506–12.
23. Thukkani AK, Agrawal K, Prince L, et al. Long-term outcomes in patients
with diabetes mellitus related to prolonging clopidogrel more than 12
MonthsAfter coronary stenting. J Am Coll Cardiol. 2015;66(10):1091–101.
24. Kandzari DE, Barker CS, Leon MB, Mauri L, Wijns W, Fajadet J, Mehran R.
Dual antiplatelet therapy duration and clinical outcomes following
treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv. 2011;
4(10):1119–28.
25. Gilard M, Barragan P, Noryani AA, et al. 6- versus 24-month dual antiplatelet
therapy after implantation of drug-eluting stents in patients nonresistant
toaspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;
65(8):777–86.
26. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting
stent implantation followed by 6- versus 12-month dual antiplatelet
therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;
64(20):2086–97.
27. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet
therapy after drug-eluting stent implantation: a randomized, controlled trial.
Circulation. 2014;129(3):304–12.
28. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after
implantation of drug-eluting stents. N Engl J Med. 2010;362(15):1374–82.
29. Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy
after drug-eluting stent implantation: a systematic review and meta-analysis
of randomized controlled trials. J Am Coll Cardiol. 2015;65(13):1298–310.
30. Yang J, Fan ZX, Yang CJ, Wang HB. A meta-analysis of randomized clinical
trials comparing shorter (less or equal than 6 months) and longer (more or
equal than 12 months) dual anti-platelet therapy following drug-eluting
coronary stents. Iran Red Crescent Med J. 2015;17(7):e26904.
31. Valgimigli M, Campo G, Monti M, Prolonging Dual Antiplatelet Treatment
After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY)
Investigators, et al. Short- versus long-term duration of dual-antiplatelet
therapy after coronary stenting: a randomized multicenter trial. Circulation.
2012;125(16):2015–26.
32. Valgimigli M, Park SJ, Kim HS, et al. Benefits and risks of long-term duration
of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of
randomized trials. Int J Cardiol. 2013;168(3):2579–87.
Bundhun et al. BMC Cardiovascular Disorders  (2016) 16:161 Page 13 of 14
33. Siddiqi OK, Smoot K, Dufour AB, et al. Outcomes with prolonged clopidogrel
therapy after coronary stenting in patients with chronic kidney disease. Heart.
2015;101(19):1569–76.
34. Fausto F, Ricardo Costa D, et al. Impact pf short versus long term DAPT in
patients with diabetes mellitus undergoing percutaneous intervention with
endeavour zotarolimus eluting stents. A subanalysis of the large, prospective,
randomized, multicenter OPTIMIZE trial. J Am Coll Cardiol. 2014;63(14):61862–3.
35. Silber S, Serruys PW, Leon MB, et al. Clinical outcome of patients with and
without diabetes mellitus after percutaneous coronary intervention with the
resolute zotarolimus-eluting stent: 2-year results from the prospectively
pooled analysis of the international global RESOLUTE program. JACC
Cardiovasc Interv. 2013;6(4):357–68.
36. Park KW, Lee JM, Kang SH, et al. Everolimus-eluting Xience v/Promus versus
zotarolimus-eluting resolute stents in patients with diabetes mellitus.
JACC Cardiovasc Interv. 2014;7(5):471–81.
37. Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between
insulin-treated and non-insulin treated diabetic patients after percutaneous
coronary intervention: a systematic review and meta-analysis. Cardiovasc
Diabetol. 2015;14:135.
38. Tanzilli G, Greco C, Pelliccia F, et al. Effectiveness of two-year clopidogrel +
aspirin in abolishing the risk of very late thrombosis after drug-eluting stent
implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J
Cardiol. 2009;104(10):1357–61.
39. Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events, and influence
of prolonged clopidogrel use after placement of drug-elutingstent data
from an observational cohort study of drug-eluting versus bare-metal
stents. JACC Cardiovasc Interv. 2008;1(5):494–503.
40. Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, Sangiorgio
P, Tondi S, Serenelli C, De Palma R, Saia F. Impact of COPD on long-term
outcome after ST-segment elevation myocardial infarction receiving primary
percutaneous coronary intervention. Chest. 2013;144(3):750–7.
41. Campo G, Pavasini R, Malagù M, Mascetti S, Biscaglia S, Ceconi C, Papi A,
Contoli M. Chronic obstructive pulmonary disease and ischemic heart
disease comorbidity: overview of mechanisms and clinical management.
Cardiovasc Drugs Ther. 2015;29(2):147–57.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bundhun et al. BMC Cardiovascular Disorders  (2016) 16:161 Page 14 of 14
